Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas

Trial Profile

Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Allogeneic stem cell therapy; Busulfan; Clofarabine; Filgrastim; Mycophenolate mofetil; Rituximab; Tacrolimus
  • Indications B cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Nov 2013 Methotrexate relaced by mycophenolate-mofetil in the drug descriptor field as reported by ClinicalTrials.gov record.
    • 27 Oct 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2012-0506).
    • 26 Oct 2012 Planned End Date changed from 1 Apr 2019 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top